Companies are preparing to release their generic versions of Hanmi Pharm’s Monterizine (Montelukast+Levocetirizin) in October at the earliest.

The generic drugs that were approved in August obtained first generic exclusivity and were able to move up their reimbursement listing date.

According to the industry sources on the 8th, the price calculation process for Monterizine generics has been completed and it is expected to be listed with reimbursement next month.

HIRA is known to have been conducting pricing calculations for Monterizine generics that applied for reimbursement after being approved in August.

The generics, which received generic exclusivity,